[1] |
WANG W, JIANG B, SUN H, RU X, SUN D, WANG L, et al. Prevalence, incidence, and mortality of stroke in China: results from a nationwide population-based survey of 480 687 adults[J]. Circulation, 2017, 135: 759-771. DOI:10.1161/CIRCULATIONAHA.116.025250 |
[2] |
WANG D, LIU J, LIU M, LU C, BRAININ M, ZHANG J. Patterns of stroke between university hospitals and nonuniversity hospitals in mainland China: prospective multicenter hospital-based registry study[J]. World Neurosurg, 2017, 98: 258-265. DOI:10.1016/j.wneu.2016.11.006 |
[3] |
BERGE E, WHITELEY W, AUDEBERT H, DE MARCHIS G M, FONSECA A C, PADIGLIONI C, et al. European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke[J]. Eur Stroke J, 2021, 6: Ⅰ-LⅩⅡ. |
[4] | |
[5] |
PANTONI L, FIERINI F, POGGESI A. Thrombolysis in acute stroke patients with cerebral small vessel disease[J]. Cerebrovasc Dis, 2014, 37: 5-13. DOI:10.1159/000356796 |
[6] |
WANG X G, ZHANG L Q, LIAO X L, PAN Y S, SHI Y Z, WANG C J, et al. Unfavorable outcome of thrombolysis in Chinese patients with cardioembolic stroke: a prospective cohort study[J]. CNS Neurosci Ther, 2015, 21: 657-661. DOI:10.1111/cns.12421 |
[7] |
ANTICOLI S, BRAVI M C, PERILLO G, SINISCALCHI A, POZZESSERE C, PEZZELLA F R, et al. Effect of cardioembolic etiology on intravenous thrombolysis efficacy for acute ischemic stroke[J]. Curr Neurovasc Res, 2016, 13: 193-198. DOI:10.2174/1567202613666160506125426 |
[8] |
ADAMS H P Jr, BENDIXEN B H, KAPPELLE L J, BILLER J, LOVE B B, GORDON D L, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment[J]. Stroke, 1993, 24: 35-41. DOI:10.1161/01.STR.24.1.35 |
[9] |
National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke[J]. N Engl J Med, 1995, 333: 1581-1587. DOI:10.1056/NEJM199512143332401 |
[10] |
HACKE W, KASTE M, FIESCHI C, VON KUMMER R, DAVALOS A, MEIER D, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS Ⅱ). Second European-Australasian Acute Stroke Study Investigators[J]. Lancet, 1998, 352: 1245-1251. DOI:10.1016/S0140-6736(98)08020-9 |
[11] | |
[12] | |
[13] |
DODDS J A, XIAN Y, SHENG S B, FONAROW G C, BHATT D L, MATSOUAKA R, et al. Thrombolysis in young adults with stroke: findings from Get With The Guidelines-stroke[J/OL]. Neurology, 2019, 92: e2784-e2792. DOI: 10.1212/WNL.0000000000007653.
|
[14] |
KAMEL H, MERKLER A E, IADECOLA C, GUPTA A, NAVI B B. Tailoring the approach to embolic stroke of undetermined source: a review[J]. JAMA Neurol, 2019, 76: 855-861. DOI:10.1001/jamaneurol.2019.0591 |
[15] |
YANG X, JING J, MENG X, LI Z, PAN Y, JIANG Y, et al. Characteristics and prognosis of patients with embolic stroke of undetermined source in China[J/OL]. Int J Stroke, 2021: 17474930211028040. DOI: 10.1177/17474930211028040.
|
[16] |
ZIVANOVIC Z, OSTOJIC Z, RAJIC S, VLAHOVIC D, MIJAJLOVIC M, JOVICEVIC M. Outcome after intravenous thrombolysis in embolic stroke of undetermined source compared to cardioembolic stroke[J]. Wien Klin Wochenschr, 2020, 132: 515-520. DOI:10.1007/s00508-020-01727-5 |
[17] |
MOLINA C A, MONTANER J, ARENILLAS J F, RIBO M, RUBIERA M, ALVAREZ-SABíN J. Differential pattern of tissue plasminogen activator-induced proximal middle cerebral artery recanalization among stroke subtypes[J]. Stroke, 2004, 35: 486-490. DOI:10.1161/01.STR.0000110219.67054.BF |
[18] |
SCHMITZ M L, SIMONSEN C Z, SVENDSEN M L, LARSSON H, MADSEN M H, MIKKELSEN I K, et al. Ischemic stroke subtype is associated with outcome in thrombolyzed patients[J]. Acta Neurol Scand, 2017, 135: 176-182. DOI:10.1111/ane.12589 |
[19] |
MEHTA A, MAHALE R, BUDDARAJU K, MAJEED A, SHARMA S, JAVALI M, et al. Intravenous thrombolysis for acute ischemic stroke: review of 97 patients[J]. J Neurosci Rural Pract, 2017, 8: 38-43. |
[20] |
SHOBHA N, FANG J, HILL M D. Do lacunar strokes benefit from thrombolysis? Evidence from the Registry of the Canadian Stroke Network[J]. Int J Stroke, 2013, 8: 45-49. DOI:10.1111/j.1747-4949.2012.00932.x |
[21] |
MUSTANOJA S, MERETOJA A, PUTAALA J, VIITANEN V, CURTZE S, ATULA S, et al. Outcome by stroke etiology in patients receiving thrombolytic treatment: descriptive subtype analysis[J]. Stroke, 2011, 42: 102-106. DOI:10.1161/STROKEAHA.110.597534 |
[22] |
VACLAVIK D, VILIONSKIS A, JATUZIS D, KARLINSKI M A, GDOVINOVA Z, KÕRV J, et al. Clinical outcome of cardioembolic stroke treated by intravenous thrombolysis[J]. Acta Neurol Scand, 2018, 137: 347-355. DOI:10.1111/ane.12880 |
[23] |
EMBERSON J, LEES K R, LYDEN P, BLACKWELL L, ALBERS G, BLUHMKI E, et al. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials[J]. Lancet, 2014, 384: 1929-1935. DOI:10.1016/S0140-6736(14)60584-5 |
[24] |
HUANG Z X, WANG Q Z, DAI Y Y, LU H K, LIANG X Y, HU H, et al. Early neurological deterioration in acute ischemic stroke: a propensity score analysis[J]. J Chin Med Assoc, 2018, 81: 865-870. DOI:10.1016/j.jcma.2018.03.011 |
[25] |
HEINSIUS T, BOGOUSSLAVSKY J, VAN MELLE G. Large infarcts in the middle cerebral artery territory. Etiology and outcome patterns[J]. Neurology, 1998, 50: 341-350. DOI:10.1212/WNL.50.2.341 |
[26] |
WAHLGREN N, AHMED N, ERIKSSON N, AICHNER F, BLUHMKI E, DÁVALOS A, et al. Multivariable analysis of outcome predictors and adjustment of main outcome results to baseline data profile in randomized controlled trials: Safe Implementation of Thrombolysis in Stroke-MOnitoring STudy (SITS-MOST)[J]. Stroke, 2008, 39: 3316-3322. DOI:10.1161/STROKEAHA.107.510768 |